면역항암제 시장 보고서(2026년)

Immuno-oncology drugs are therapies that use medications to either enhance or suppress the immune system to help the body fight cancer, infections, and other diseases. They utilize naturally occurring or lab-produced compounds to strengthen the immune response and assist in identifying and eliminating cancer cells.

The main types of immuno-oncology drugs are monoclonal antibodies, immune checkpoint inhibitors, immune system modulators, cancer vaccines, and others. Monoclonal antibodies are produced by cloning a single white blood cell, ensuring that all subsequent antibodies originate from the same parent cell. These drugs are applied in treating conditions such as melanoma, lung cancer, blood cancers, renal cell carcinoma, prostate cancer, bladder cancer, and others, and are used across hospitals, clinics, ambulatory surgical centers, and cancer research institutes.

Tariffs have influenced the immuno-oncology drugs market by increasing the cost of imported biologics, monoclonal antibodies, and cancer vaccines, particularly affecting hospitals and clinics in North America, Europe, and Asia-Pacific regions. Segments like immune checkpoint inhibitors and adoptive cell transfer therapies are most impacted due to reliance on imported components and reagents. While tariffs have raised treatment costs and caused supply chain challenges, they have also encouraged domestic manufacturing, local R&D investment, and innovation in cost-effective immuno-oncology therapies.

The immuno-oncology drugs market research report is one of a series of new reports from The Business Research Company that provides immuno-oncology drugs market statistics, including immuno-oncology drugs industry global market size, regional shares, competitors with a immuno-oncology drugs market share, detailed immuno-oncology drugs market segments, market trends and opportunities, and any further data you may need to thrive in the immuno-oncology drugs industry. This immuno-oncology drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The immuno-oncology drugs market size has grown rapidly in recent years. It will grow from $120.37 billion in 2025 to $136.15 billion in 2026 at a compound annual growth rate (CAGR) of 13.1%. The growth in the historic period can be attributed to limited availability of immuno-oncology drugs, reliance on conventional chemotherapy, increasing prevalence of cancers like melanoma and lung cancer, growing oncology-focused research initiatives, early regulatory approvals for monoclonal antibodies.

The immuno-oncology drugs market size is expected to see rapid growth in the next few years. It will grow to $226.31 billion in 2030 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to development of bispecific antibodies and oncolytic virus therapies, expansion of personalized immunotherapy solutions, increasing investment in adoptive cell transfer therapies, rising healthcare expenditure on cancer treatment, integration of digital platforms for patient monitoring and clinical trials. Major trends in the forecast period include rising adoption of immune checkpoint inhibitors across multiple cancer types, growth in development of cancer vaccines and adoptive cell therapies, increasing focus on personalized immuno-oncology treatments, expansion of hospital and ambulatory surgical center-based immunotherapy programs, rising clinical trials and research activities in monoclonal antibodies.

The escalating incidence of cancer cases is poised to accelerate the immuno-oncology drugs market ahead. Cancer involves rogue cells multiplying wildly, potentially metastasizing and disrupting bodily functions. This surge stems from aging demographics, lifestyle shifts, and sharper detection tools. Immuno-oncology drugs advance this landscape by rallying the immune system to hunt and destroy tumors, delivering potent, targeted options. For instance, in 2023, Cancer Australia, an Australia-based government agency, tallied 164,694 new diagnoses and 51,269 deaths, led by prostate, breast, melanoma, colorectal, and lung cancers; rare types claimed about one-third of cases and 42% of fatalities. Therefore, the increasing incidence of cancer cases is driving the growth of the immuno-oncology drugs market.

Leading companies in the immuno-oncology drugs market are teaming up to craft and launch cutting-edge checkpoint antibodies for superior cancer outcomes. Strategic collaborations spark breakthroughs via shared expertise, hastening combo therapies, custom care, and smart delivery methods. For instance, in March 2023, BioNTech SE, a Germany-based company, allied with OncoC4 Inc, a US-based pharmaceutical company, to jointly build and market a checkpoint antibody-the anti-CTLA-4 monoclonal contender ONC-392-across diverse solid tumors.

In November 2023, AbbVie Inc., a US-based company, bought ImmunoGen for $10.1 billion. Through this acquisition, AbbVie seeks to broaden its lineup with ImmunoGen's immuno-oncology prowess. ImmunoGen Inc. is a US-based company that offers immune checkpoint inhibitors.

Major companies operating in the immuno-oncology drugs market are F. Hoffmann-La Roche Ltd., Merck & Co., Bristol-Myers Squibb Company, Amgen Inc, Johnson & Johnson, AstraZeneca Plc, Eli Lilly and Company, Novartis International AG, Pfizer Inc., Sanofi S.A., Arlak Biotech, Apikos Pharma, Kolaz biotech, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Takeda Pharmaceuticals, Astellas Pharma Inc, Otsuka Pharmaceutical Co Ltd, Legend Biotech Co, Zai Lab, Daiichi Pharmaceutical and Sankyo, AQVIDA GmbH, GlaxoSmithKline plc, Affimed Therapeutics, Autolus Therapeutics, Cellectis, Celyad, GammaDelta Therapeutics, Immunocore, Celon Pharma, Veropharm, Biocad, Selvita, OncoArendi Therapeutics Mabion, Fate Therapeutics, Forty-Seven, Arcus Biosciences, Gritstone Oncology, Rakuten Medical, Rubius Therapeutics, Allogene Therapeutics, Celgene Corporation, Bayer AG, Incyte Corporation, Recepta Biopharma, Sandoz Brazil, Life Pharma, Julphar, NewBridge Pharmaceuticals.

North America was the largest region in the immuno-oncology drugs market in 2025. The regions covered in the immuno-oncology drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the immuno-oncology drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The immuno-oncology drugs market consists of sales of bevacizumab, alectinib, ibrutinib, imatinib, and palbociclib. Values in this market are factory gate values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Immuno-Oncology Drugs Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses immuno-oncology drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for immuno-oncology drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The immuno-oncology drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Immune Checkpoint Inhibitors; Immune System Modulators; Other Monoclonal Antibodies; Cancer Vaccines; Other Types
• 2) By Therapeutic Application: Melanoma; Lung Cancer; Blood Cancer; Renal Cell Carcinoma; Bladder Cancer; Other Therapeutic Application
• 3) By End-Users: Hospitals; Clinics; Ambulatory Surgical Centers; Other End-Users
• Subsegments:
• 1) By Immune Checkpoint Inhibitors: PD-1 Inhibitors; PD-L1 Inhibitors; CTLA-4 Inhibitors
• 2) By Immune System Modulators: Cytokines; Interferons; Colony-Stimulating Factors
• 3) By Other Monoclonal Antibodies: Targeted Monoclonal Antibodies; Bispecific Antibodies
• 4) By Cancer Vaccines: Preventive Cancer Vaccines; Therapeutic Cancer Vaccines
• 5) By Other Types: Adoptive Cell Transfer Therapies; Oncolytic Virus Therapies
• Companies Mentioned: F. Hoffmann-La Roche Ltd.; Merck & Co.; Bristol-Myers Squibb Company; Amgen Inc; Johnson & Johnson; AstraZeneca Plc; Eli Lilly and Company; Novartis International AG; Pfizer Inc.; Sanofi S.A.; Arlak Biotech; Apikos Pharma; Kolaz biotech; CStone Pharma; CARsgen Therapeutics; JW Therapeutics; BeiGene; Takeda Pharmaceuticals; Astellas Pharma Inc; Otsuka Pharmaceutical Co Ltd; Legend Biotech Co; Zai Lab; Daiichi Pharmaceutical and Sankyo; AQVIDA GmbH; GlaxoSmithKline plc; Affimed Therapeutics; Autolus Therapeutics; Cellectis; Celyad; GammaDelta Therapeutics; Immunocore; Celon Pharma; Veropharm; Biocad; Selvita; OncoArendi Therapeutics Mabion; Fate Therapeutics; Forty-Seven; Arcus Biosciences; Gritstone Oncology; Rakuten Medical; Rubius Therapeutics; Allogene Therapeutics; Celgene Corporation; Bayer AG; Incyte Corporation; Recepta Biopharma; Sandoz Brazil; Life Pharma; Julphar; NewBridge Pharmaceuticals.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Immuno-Oncology Drugs Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Immuno-Oncology Drugs Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Immuno-Oncology Drugs Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Immuno-Oncology Drugs Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.3 Industry 4.0 & Intelligent Manufacturing
  • 4.1.4 Artificial Intelligence & Autonomous Intelligence
  • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Rising Adoption Of Immune Checkpoint Inhibitors Across Multiple Cancer Types
  • 4.2.2 Growth In Development Of Cancer Vaccines And Adoptive Cell Therapies
  • 4.2.3 Increasing Focus On Personalized Immuno-Oncology Treatments
  • 4.2.4 Expansion Of Hospital And Ambulatory Surgical Center-Based Immunotherapy Programs
  • 4.2.5 Rising Clinical Trials And Research Activities In Monoclonal Antibodies

5. Immuno-Oncology Drugs Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Clinics
• 5.3 Ambulatory Surgical Centers
• 5.4 Oncology Research Centers
• 5.5 Specialty Cancer Treatment Centers

6. Immuno-Oncology Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Immuno-Oncology Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Immuno-Oncology Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Immuno-Oncology Drugs Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Immuno-Oncology Drugs Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Immuno-Oncology Drugs Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Immuno-Oncology Drugs Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Immuno-Oncology Drugs Market Segmentation

• 9.1. Global Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Immune Checkpoint Inhibitors, Immune System Modulators, Monoclonal Antibodies, Cancer Vaccines, Others
• 9.2. Global Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer, Other Therapeutic Application
• 9.3. Global Immuno-Oncology Drugs Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Clinics, Ambulatory Surgical Centers, Others
• 9.4. Global Immuno-Oncology Drugs Market, Sub-Segmentation Of Immune Checkpoint Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors
• 9.5. Global Immuno-Oncology Drugs Market, Sub-Segmentation Of Immune System Modulators, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Cytokines, Interferons, Colony-Stimulating Factors
• 9.6. Global Immuno-Oncology Drugs Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Targeted Monoclonal Antibodies, Bispecific Antibodies
• 9.7. Global Immuno-Oncology Drugs Market, Sub-Segmentation Of Cancer Vaccines, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Preventive Cancer Vaccines, Therapeutic Cancer Vaccines
• 9.8. Global Immuno-Oncology Drugs Market, Sub-Segmentation Of Others, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Adoptive Cell Transfer Therapies, Oncolytic Virus Therapies

10. Immuno-Oncology Drugs Market Regional And Country Analysis

• 10.1. Global Immuno-Oncology Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Immuno-Oncology Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Immuno-Oncology Drugs Market

• 11.1. Asia-Pacific Immuno-Oncology Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Immuno-Oncology Drugs Market, Segmentation By Type, Segmentation By Therapeutic Application, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Immuno-Oncology Drugs Market

• 12.1. China Immuno-Oncology Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Immuno-Oncology Drugs Market, Segmentation By Type, Segmentation By Therapeutic Application, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Immuno-Oncology Drugs Market

• 13.1. India Immuno-Oncology Drugs Market, Segmentation By Type, Segmentation By Therapeutic Application, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Immuno-Oncology Drugs Market

• 14.1. Japan Immuno-Oncology Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Immuno-Oncology Drugs Market, Segmentation By Type, Segmentation By Therapeutic Application, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Immuno-Oncology Drugs Market

• 15.1. Australia Immuno-Oncology Drugs Market, Segmentation By Type, Segmentation By Therapeutic Application, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Immuno-Oncology Drugs Market

• 16.1. Indonesia Immuno-Oncology Drugs Market, Segmentation By Type, Segmentation By Therapeutic Application, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Immuno-Oncology Drugs Market

• 17.1. South Korea Immuno-Oncology Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Immuno-Oncology Drugs Market, Segmentation By Type, Segmentation By Therapeutic Application, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Immuno-Oncology Drugs Market

• 18.1. Taiwan Immuno-Oncology Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Immuno-Oncology Drugs Market, Segmentation By Type, Segmentation By Therapeutic Application, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Immuno-Oncology Drugs Market

• 19.1. South East Asia Immuno-Oncology Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Immuno-Oncology Drugs Market, Segmentation By Type, Segmentation By Therapeutic Application, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Immuno-Oncology Drugs Market

• 20.1. Western Europe Immuno-Oncology Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Immuno-Oncology Drugs Market, Segmentation By Type, Segmentation By Therapeutic Application, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Immuno-Oncology Drugs Market

• 21.1. UK Immuno-Oncology Drugs Market, Segmentation By Type, Segmentation By Therapeutic Application, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Immuno-Oncology Drugs Market

• 22.1. Germany Immuno-Oncology Drugs Market, Segmentation By Type, Segmentation By Therapeutic Application, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Immuno-Oncology Drugs Market

• 23.1. France Immuno-Oncology Drugs Market, Segmentation By Type, Segmentation By Therapeutic Application, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Immuno-Oncology Drugs Market

• 24.1. Italy Immuno-Oncology Drugs Market, Segmentation By Type, Segmentation By Therapeutic Application, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Immuno-Oncology Drugs Market

• 25.1. Spain Immuno-Oncology Drugs Market, Segmentation By Type, Segmentation By Therapeutic Application, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Immuno-Oncology Drugs Market

• 26.1. Eastern Europe Immuno-Oncology Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Immuno-Oncology Drugs Market, Segmentation By Type, Segmentation By Therapeutic Application, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Immuno-Oncology Drugs Market

• 27.1. Russia Immuno-Oncology Drugs Market, Segmentation By Type, Segmentation By Therapeutic Application, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Immuno-Oncology Drugs Market

• 28.1. North America Immuno-Oncology Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Immuno-Oncology Drugs Market, Segmentation By Type, Segmentation By Therapeutic Application, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Immuno-Oncology Drugs Market

• 29.1. USA Immuno-Oncology Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Immuno-Oncology Drugs Market, Segmentation By Type, Segmentation By Therapeutic Application, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Immuno-Oncology Drugs Market

• 30.1. Canada Immuno-Oncology Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Immuno-Oncology Drugs Market, Segmentation By Type, Segmentation By Therapeutic Application, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Immuno-Oncology Drugs Market

• 31.1. South America Immuno-Oncology Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Immuno-Oncology Drugs Market, Segmentation By Type, Segmentation By Therapeutic Application, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Immuno-Oncology Drugs Market

• 32.1. Brazil Immuno-Oncology Drugs Market, Segmentation By Type, Segmentation By Therapeutic Application, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Immuno-Oncology Drugs Market

• 33.1. Middle East Immuno-Oncology Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Immuno-Oncology Drugs Market, Segmentation By Type, Segmentation By Therapeutic Application, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Immuno-Oncology Drugs Market

• 34.1. Africa Immuno-Oncology Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Immuno-Oncology Drugs Market, Segmentation By Type, Segmentation By Therapeutic Application, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Immuno-Oncology Drugs Market Regulatory and Investment Landscape

36. Immuno-Oncology Drugs Market Competitive Landscape And Company Profiles

• 36.1. Immuno-Oncology Drugs Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Immuno-Oncology Drugs Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Immuno-Oncology Drugs Market Company Profiles
  • 36.3.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Merck & Co. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Amgen Inc Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis

37. Immuno-Oncology Drugs Market Other Major And Innovative Companies

• AstraZeneca Plc, Eli Lilly and Company, Novartis International AG, Pfizer Inc., Sanofi S.A., Arlak Biotech, Apikos Pharma, Kolaz biotech, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Takeda Pharmaceuticals, Astellas Pharma Inc, Otsuka Pharmaceutical Co Ltd

38. Global Immuno-Oncology Drugs Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Immuno-Oncology Drugs Market

40. Immuno-Oncology Drugs Market High Potential Countries, Segments and Strategies

• 40.1 Immuno-Oncology Drugs Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Immuno-Oncology Drugs Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Immuno-Oncology Drugs Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer